Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain

Inclusion Criteria: * Comprehension of clinical trial and signed informed consent before initiation. * Male or female adults, age 18 to 70. * Clinical history of neuropathic pain secondary to SCI * Patients with an AIS of A, B, C or D according to the American Spinal Cord Injury Association (ASIA) Impairment Scale. * Persistent neuropathic pain from 1 month up to 6 months after spinal cord injury. * Non-evoked at-level pain with ≥ 2 intensity measured with the numerical rating scale (0-10). * Non-evoked/evoked at-level pain corresponding to the area of sensory alteration, and within the three dermatomes below the neurological level of the spinal cord injury. * Formal acceptance of disponibility for all programmed clinical trial visits and other protocol requisites. * Females of child bearing age must demonstrate a negative pregnancy test (performed on screening and subsequent follow up visits) and use a reliable birth control method including abstinence of sexual activity throughout the duration of the study and for at last 28 days after termination of the clinical trial. Exclusion Criteria: * Previous or actual use of gabapentin. * Creatinine clearance level \<60 ml/min. * Neuropathic pain unrelated to spinal cord injury. * Lactose intolerance, Lapp lactase insufficiency or glucose malabsorption * Platelet count \< 100x103/µl. * White blood cell count \<2.5 x103/µl. * Neutrophil count \<1.5 x103/µl. * Planned surgery during the clinical trial. * Patients with peripheral neuropathic pain. * Previous history of malignant melanoma. * History of malignant tumors, except for in situ uterine cervix carcinoma, in situ basocellular or spinocellular cutaneous carcinomas, superficial bladder tumors (Ta and Tis) with a complete treatment response up to 10 years. Patients with history of lymphoma or breast cancer will be allowed to participate in the trial if a complete treatment response has been observed up to 20 years. * Chronic or active infection requiring a systemic therapy, chronic kidney infections, chronic lung infections with bronchiectasias, Mycobacterium tuberculosis infection, active Hepatitis B or C. Diagnosis of latent TB confection should be performed according to the local guidelines. * Severe heart diseases such as unstable angina, cardiopathy during the first 6 months after a myocardial infarction, grade III or IV of the New York Heart Association scale for congestive heart failure. * Unknown kidney, liver, gastrointestinal, endocrine, lung, hematological, neurological or psychiatric comorbidities. * Subjects administered with an experimental or non-commercial drug during the 4 weeks prior to the trial. * Patients participating in other clinical studies. * Patients that are not competent for completing required tasks (eg. alcohol or drug related problems or psychiatric disorders). * Subjects unable to be examined with radiological MRI exploration due to contraindications. * Pregnancy or breastfeeding. * Any other patient condition that is deemed unsuitable for subject inclusion in the trial according to the research team.